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Insidious Mycobacterium tuberculosis infection causing
tubulointerstitial nephritis is a rare disorder. Here we
report on a single-center case series of patients with
tubulointerstitial nephritis due to tuberculosis, addressing
clinicopathologic features and treatment outcome. Twenty-
five adult patients with clinical evidence of tuberculosis and
significant renal disease were assessed, 17 of whom had a
kidney biopsy and were subsequently diagnosed with
chronic granulomatous tubulointerstitial nephritis as the
primary lesion. All patients were given standard
antitubercular treatment, with some receiving
corticosteroids, and showed a good response in clinical
symptoms and inflammatory markers. Nine of the 25
patients, however, started renal replacement therapy
within 6 months of presentation. Of the remaining 16,
renal function improved for up to a year after presentation
but subsequently declined through a median follow-up
of 36 months. This case series supports that chronic
tubulointerstitial nephritis is the most frequent kidney biopsy
finding in patients with renal involvement from tuberculosis.
Thus, a kidney biopsy should be considered in the clinical
evaluation of kidney dysfunction with tuberculosis since
tubulointerstitial nephritis presents late with advanced
disease. A low threshold of suspicion in high-risk populations
might lead to earlier diagnosis and treatment, preserving
renal function and delaying initiation of renal replacement
therapy.
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Tuberculosis (TB) of the genitourinary tract, like other forms
of the disease, is caused by members of the Mycobacterium
tuberculosis complex. Globally, it is estimated that 9.2 million
new cases and 1.7 million deaths from TB occurred in 2006,
of which 0.7 million cases and 0.2 million deaths were in
human immunodeficiency virus (HIV)-positive people.1
Most of the TB infections are in the lung, but extrapulmon-
ary TB accounts for 20–25% of the total worldwide disease
burden, and in 12% of cases there is both pulmonary and
extrapulmonary TB.2 The genitourinary system is the second
most common site of extrapulmonary TB, affected in 15–20%
of nonpulmonary infections, but isolated genitourinary TB is
a feature in just 4% of patients.2 The global incidence of TB
per capita peaked around 2003 and appears to have stabilized
or begun to decline by 2006,1 but the incidence of TB in
the United Kingdom and particularly in London continues
to rise.3 The incidence of this disease is much higher in ethnic
minority populations in the United Kingdom, and has also
been found to be higher in patients with chronic renal
failure.4–6 Although the epidemiology of pulmonary TB in
England and Wales and identification of at-risk groups is well
defined from previous National surveys,7 the epidemiology of
genitourinary TB is not well described.
TB can cause renal impairment in a variety of ways. TB of
the kidneys leading to renal failure is an important, although
rare, cause of renal failure as it is potentially treatable.
Genitourinary TB has been well described in the form of a
‘classical’ presentation with sterile pyuria, pelvicalyceal
deformities, and (usually) systemic symptoms.8 However,
tubulointerstitial nephritis (TIN) due to TB is a more
insidious and less well-recognized form of renal involvement
in TB, which has previously been described in a small case
series from our center.9 Subsequent case reports have been
infrequent and with small patient numbers. There is evidence
that subclinical TIN was present in 425% of patients with
pulmonary TB in a small biopsy series.10 However, this is
likely to include patients with drug-induced interstitial
nephritis, as most of the patients were on treatment with
antitubercular agents at the time of biopsy. Tuberculous TIN
has been found to be more common in patients from
the Indian subcontinent,9 and has been postulated to be
because of a pauci-immune-complex-mediated inflamma-
tory reaction.11 A single-center series of 394 consecutive
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patients undergoing diagnostic renal biopsy in west London
has also shown an increased incidence of interstitial nephritis
of unknown etiology in the subgroup of patients from the
Indian subcontinent, with 15 out of the 19 patients with
unexplained interstitial nephritis being of Indian origin.12
The mainstay of treatment in this disease is the standard
recommended regimen of antitubercular therapy consisting
of 6 months of isoniazid and rifampicin, supplemented in the
first 2 months with pyrazinamide and ethambutol.13 How-
ever, in view of the evidence for irreversible optic neuritis
with ethambutol treatment in patients with significant renal
impairment,14 some renal units have a policy of withholding
ethambutol treatment and initiating treatment with three
agents followed by standard course of two agents. Our unit
has a policy of individualized therapy under the supervision
of a nephrologist and a chest physician specializing in TB in
such patients. There are no data on steroid therapy in TB TIN
and neither the British Thoracic Society/National Institute
for Clinical Excellence in the United Kingdom nor the Centre
for Disease Control/American Thoracic Society in the
United States15 specifically recommend steroid therapy in
the treatment of TB TIN. However, this is with the caveat that
the guidelines are focused on the treatment of classical
deforming genitourinary TB rather than TB TIN. The
evidence for steroid treatment in idiopathic TIN remains ill
defined16 in the absence of trial data, which is not surprising
in view of the rarity of the condition. Our policy now is to
initiate steroid treatment at the dose of 0.5mg per kg body
weight of prednisolone in patients with severe and progres-
sive renal dysfunction and a diagnosis of TB TIN, with
tapering of the steroid dose after 2 months of treatment.
There is a paucity of data on the impact of therapy on
long-term outcome, the risk of drug toxicity, and progression
of chronic kidney disease (CKD) in TB TIN. We present the
largest single-center series of TIN due to TB treated with a
combination of antitubercular treatment and corticosteroids.
RESULTS
Patients
In all, 25 adult patients were assessed by the renal unit
between January 2001 and August 2008 with clinical evidence
of TB and significant renal disease. In total, 17 patients (68%)
underwent a renal biopsy. The cohort of 25 patients included
2 patients (8%) who had HIV co-infection, of whom one
underwent a renal biopsy.
The median age at presentation was 40 years (range 20–75
years) with 11 male patients. Of the 25 patients, 19 were of
Indo-Asian ethnic origin and 6 patients were of Black African
origin (Table 1). Co-morbidity varied with the country of
origin of the patient, with two out of six patients of Black
African origin presenting with HIV co-infection and sputum-
positive TB; the remaining patients did not have HIV co-
infection and presented with more indolent symptoms. The
total length of stay in the United Kingdom varied from
6 months to 30 years, with six patients having been here for
420 years; three were born in this country.
Of the eight non-biopsied patients, five had microbiolo-
gical evidence of TB (Figure 1). Three had presented with
M. tuberculosis culture-positive sputum, of whom one patient
had HIV infection with miliary shadowing on chest X-ray,
and an early-morning urine culture (EMU) positive for
TB. One patient developed granulomatous uveitis with
M. tuberculosis culture-positive tuberculous peritonitis after
presenting with dialysis-requiring renal failure. One patient
had axillary and cervical lymphadenopathy with histological
and microbiological evidence of TB on lymph node biopsy.
The remaining three non-biopsied patients had pyrexia of
unknown origin with systemic symptoms of disease, of
whom one had three family members with active TB living in
the same house, one had retroperitoneal and mediastinal
lymphadenopathy, and one had chest X-ray evidence of old
TB. All eight patients not biopsied had small (o8.5 cm)
smooth kidneys on imaging by computerized tomography or
ultrasound examination. The patient with HIV co-infection
had normal-sized (11.5 cm, 12.0 cm bipolar length) kidneys
on ultrasonography but was not biopsied as he was EMU
positive.
Of the 17 patients who underwent a renal biopsy, all
had chronic renal impairment, were treatment-naive for HIV
and TB, and were diagnosed with TIN.
Of these 17 patients, 8 (47%) were asymptomatic and
were biopsied on the basis of active urinary sediments with a
rapidly progressive renal failure. Of these eight, five (62.5%)
gave a history of systemic symptoms of unexplained weight
loss and fever over the preceding 4 to 12 months.
Additionally, three patients (37.5%) gave a history of urinary
frequency and nocturia. Two patients were 31- and 42-year-
old males without significant prostatomegaly or residual
urine, whereas the third patient was a 35-year-old female
with dysuria and urinary frequency. Two patients were
asymptomatic at presentation.
Two out of the eight patients with no evidence of TB
elsewhere were initially treated empirically with oral steroids
Table 1 | Demographics of patients with tubercular interstitial
nephritis
Parameter Value
Median age (range) 40 (20–75)
Male gender (%) 44
Race and country of birth
Black/African 6
Somalia 3
Zambia 1
Uganda 1
Ethiopia 1
Indo-Asian 19
South Asian 13
Kenya 3
United Kingdom 3
Median follow-up (range) 36 months
(6–72 months)
South Asian patients included patients born in India, Pakistan, and Bangladesh.
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for granulomatous TIN with progressive renal impairment.
Both became acutely unwell over a period of 2 to 3 weeks.
The first patient, a 37-year-old female of Indo-Asian
origin, developed progressive pulmonary infiltrates with
sputum smear-positive pulmonary TB. The second patient
was a 39-year-old male, also of Indo-Asian origin, who
developed an exudative peritonitis that was culture positive
for M. tuberculosis and revealed granulomata on omental
biopsy.
The remaining nine biopsied patients had evidence of TB
elsewhere. Of these, two patients had cavitating sputum
smear-positive pulmonary TB and two patients had histolo-
gical evidence of cervical tuberculous lymphadenitis along
with pulmonary involvement (one exudative pleural effusion,
one bilateral hilar lymphadenopathy). One patient had
inguinal cold abscesses with histological and microbiological
evidence of TB from skin biopsies. One (male, 72 years old)
patient had caseating granulomata on a prostatic biopsy
performed to investigate prostatic symptoms and a high
prostate-specific antigen following an initial diagnosis of
idiopathic TIN. One patient was diagnosed as having
idiopathic TIN on renal biopsy and investigated for hilar
and subcarinal lymphadenopathy via an ultrasound-guided
transbronchial fine needle aspiration that revealed culture-
positive M. tuberculosis. One patient had evidence of para-
aortic lymphadenopathy and another had bilateral hilar
lymphadenopathy on imaging, both of which were not
technically possible to biopsy or aspirate.
Histology
All the 16 renal biopsies from patients without HIV
co-infection revealed an interstitial inflammation with
eosinophilia and granulomata (Figure 2), whereas caseating
granulomata were found in only 3 out of the 16 (18.7%)
biopsies. The biopsy from the single patient with HIV
co-infection showed severe TIN with eosinophilia but no
25 Patients
17 Biopsied 8 Not biopsied
All had interstital
inflammation, eosinophilia,
and granulomata
3 Sputum culture-
positive PTB
8 Had progressive
renal dysfunction
9 Had evidence
of TB elsewhere
1 Cervical, axillary
lymphadenopathy
1 Strong family
history of TB
1 Retroperitoneal
and abdominal
lymphadenopathy
1 Evidence of old TB
on chest X-Ray
1 TB peritonitis
Figure 1 |Diagnostic breakdown of all patients referred with tuberculosis and renal disease. PTB, pulmonary tuberculosis.
a b
Figure 2 |Histological features of tuberculous tubulointerstitial nephritis (TB TIN). (a) Caseating granuloma and (b) Langhans giant cell
formation.
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granuloma formation, on a background of HIV-associated
focal segmental glomerulosclerosis and a culture-positive
EMU sample for M. tuberculosis.
None of the renal biopsy cores examined were positive
for acid and alcohol fast bacilli by Ziehl–Neelsen staining
or culture. Out of 17 biopsy cores examined, just 2 had
mesangial IgG deposition, which was thought to be
nonspecific IgG trapping on a scarred glomerulus. There
was no evidence of immune-complex deposition on electron
microscopy.
PCR of the clinicopathological samples has been shown
to have a poor sensitivity in paraffin-embedded samples.
A retrospective study using PCR-based diagnosis of extra-
pulmonary TB17 showed that 31.9% of paraffin-embedded
tissue was positive for Mycobacterial species. We therefore
selected five patients from our cohort with a clinical,
histological, and/or microbiological diagnosis of M. tubercu-
losis and submitted them for reverse hybridization-based
line probe assay (LiPA; the INNO-LiPA Rif. TB) at the HPA
National Mycobacterium Reference Laboratory, which is
based at our parent institute and is a supra-national reference
unit for diagnosis and characterization of mycobacterial
disease.18
The characteristics of the five patients submitted to the
LiPA probe were:
Case 1. Chronic granulomatous TIN on renal biopsy,
and widespread lymphadenopathy with a transbronchial
mediastinal lymph node aspirate culture positive for
M. tuberculosis.
Case 2. Sputum culture positive for M. tuberculosis with
TB with heavily scarred kidneys with granulomatous TIN
on biopsy.
Case 3. Prostatic biopsy suggestive of TB (caseating
granulomata) followed by a native renal biopsy showing
chronic granulomatous TIN.
Case 4. Renal biopsy showed TIN, treated with steroids as
idiopathic TIN, developed exudative ascites, fully sensitive
M. tuberculosis cultured from peritoneal fluid.
Case 5. Renal biopsy showed caseating granulomata with
good clinical and biochemical response to antitubercular
treatment.
However, in spite of careful patient selection to ensure that
patients with high clinical probability of mycobacterial DNA
in kidneys were included, all five patients were negative for
M. tuberculosis on PCR. Therefore, not all histology samples
were submitted for M. tuberculosis PCR via the LiPA probe.
We feel that the poor pick-up rate of mycobacterial DNA
by PCR in extrapulmonary samples was worsened in our
patients by the fact that the samples were old (average age
4 years) and were negative on Ziehl–Neelsen staining.
Treatment
All patients were treated with standard 6 months of anti-
tubercular treatment, with an initial 2 months of induction
period of three (occasionally four) drugs including rifampi-
cin, under both a nephrologist and a chest physician.
All patients were also started on steroids in the form of
prednisolone 20mg. The prednisolone was then tapered off
at 5mg per week with a view toward completely stopping it
at the end of the first 2 months of treatment.
Two patients had to discontinue treatment temporarily
because of side effects of anti-TB medication. The patient
with abdominal, axillary, and chest wall cold abscesses
developed a drug-induced dermatitis whereas the one with
coexistent TB prostatitis developed drug-induced hepatitis.
Both were managed by stopping all medication and
sequential re-introduction of therapy. All patients managed
to complete 6 months of antitubercular treatment.
The average calculated estimated glomerular filtration rate
(eGFR) as calculated by the MDRD (Modification of Diet in
Renal Disease) equation19 for all patients at presentation was
13.39ml/min (95% confidence interval 8.02–20.08). Table 2
and Figure 3 summarize changes in eGFR in response to
antitubercular treatment.
All patients showed a good clinical response in systemic
symptoms to antitubercular treatment, with a median follow-
up of 36 months (range 6–72 months). Out of 25 patients,
9 patients started RRT within 6 months of presentation.
In the remaining 16 patients, the mean eGFR was
18.1±2.2ml/min at presentation, 29.8±12.7ml/min at
6 months (eGFR at presentation vs 6 months, P¼ 0.0168),
and 32.74±14.4ml/min at 1 year (eGFR at presentation vs
1 year¼ 0.013). There was no relationship between response
to treatment and degree of initial proteinuria with significant
improvement in eGFR at 1 year.
We then investigated the change in eGFR during follow-up
of these patients. After the first year, the change in eGFR was
–7.21ml/min/year for CKD 3 and 7.065ml/min/year for
CKD 4 over a median follow-up of 43 months (range 26–60
months) for CKD 3 and 31 months (range 12–50 months) for
CKD 4. The mean proteinuria at presentation for CKD 3
patients was 1.48±0.4 g per 24 h and for CKD 4 patients was
1.312±0.55 g per 24 h with preserved serum albumin.
The mean proteinuria at presentation for all patients was
1.31±0.83 g per 24 h (n¼ 25) that decreased to 0.25±0.18
(n¼ 16) by the end of 6 months of treatment (P¼ 0.4819).
For patients who did not require dialysis by the end of first
year, mean proteinuria at presentation was 1.47±0.13 g per
24 h (n¼ 16) that decreased to 0.93±0.24 g per 24 h (n¼ 16)
by the end of 6 months (P¼ 0.0404).
The mean C-reactive protein at presentation for all
patients was 36.79±10.45 (n¼ 25) that decreased to
7.652±1.202 (n¼ 25; P¼ 0.0094) at 6 months. Erythrocyte
sedimentation rate was only available in 19 out of the 25
patients. The mean erythrocyte sedimentation rate at
presentation was 54.32±8.478 cm/h (n¼ 19) that decreased
to 29.62±4.450 (n¼ 19) at 6 months (P¼ 0.0313).
Interestingly, urine microscopy and culture results were
available in 23 out of 25 patients. Although sterile
leukocyturia has been thought to be common in renal TB,
just 13 of the 23 (56.5%) patients had sterile leukocyturia in
our series.
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DISCUSSION
Although rare, TB TIN is a disease with poor renal prognosis.
Diagnosis is limited by insidious symptoms and advanced
disease at the time of presentation. Early diagnosis and
treatment was linked to significant recovery of function in
our small cohort of patients.
Alternative causes such as renal sarcoidosis and drugs (for
example, antibiotics, nonsteroidal anti-inflammatory agents)
must also be excluded from the differential diagnosis of
granulomatous TIN. Renal sarcoidosis has been described in
a case series from our center.20 Renal manifestations in
sarcoidosis include granulomatous TIN that is infrequently
associated with ceseation or asteroid bodies, in a majority of
patients, with a minority presenting with other glomerular
lesions. All patients with renal sarcoidosis had systemic
evidence of the disease, with good response to systemic
corticosteroid treatment irrespective of the degree of
tubulointerstitial scarring, and were maintained on low-dose
steroid therapy with significant improvement in eGFR.
In contrast, all patients in the current series showed excellent
response in response to antitubercular therapy in systemic
symptoms and inflammatory markers.
In our group of patients, 19 patients were of Indo-Asian
origin (Table 1), of whom three were born in the United
Kingdom and three in Kenya, with 13 patients having been
born in the Indian subcontinent. The patients born in the
Indian subcontinent or East Africa had a median duration of
stay in the United Kingdom of 112 months (9.3 years,
mean±s.d. 172.4±133 months), suggesting reactivation of
previous TB infection or a long-standing process rather than
an acute re-infection locally. This population cross-section is
in keeping with previous experience of TB TIN, which has
been reported mainly in Indo-Asian ethnic groups.9–11,21,22 In
our series, three patients with TB TIN without HIV infection
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Figure 3 |Response to anti-tubercular treatment: individual
estimated glomerular filtration rates (eGFRs) at presentation,
completion of treatment (6 months), and 1 year (censored for
patients who started renal replacement therapy within 1
year). Po0.05 for eGFR at presentation vs 6 months and 1 year
and presentation vs current eGFR. MDRD, Modification of Diet in
Renal Disease.
Table 2 | Patient data
No. Age/gender Follow-up (mo) Presenting eGFR Treatmenta Outcome/last eGFR
1. 41/M 6 10.9 2HRZE+4HR Lost to F/U
2. 35/F 60 10.65 2HRZ+4HR HDx at year 4, Tx at year 5
3. 34/F 24 13.3 2HRZE+4HR 51.37
4. 51/F 36 10.1 2HRZE+4HR 9.8
5. 38/F 48 4.66 2HRZE+4HR Started PD at 30 mo, Tx at 38 mo
6. 74/M 50 10.9 2HRZ+4HR Started HDx at 22 mo
7. 73/F 58 18.6 2HRZ+4HR Started HDx at 54 mo
8. 45/F 24 42.77 2HRZE+4HR 62.08
9. 20/M 26 3.98 2RZE+4R, Moxb HDx immediately
10. 23/M 21 1.59 2HRZE+4HR HDx immediately, Tx at 18 mo
11. 51/M 23 4.32 2HRZE+4HR HDx immediately
12. 39/M 12 4.1 2HRZE+HR HDx immediately
13. 37/F 50 4.3 2HRZE+4HR HDx immediately, Tx at 46 mo
14. 58/F 68 5.83 2HRZE+4HR PD immediately, HDx at 32 mo
15. 56/M 48 9.8 2HRZE+4HR HDx immediately
16. 24/F 35 5.84 2HRZE+4HR PD immediately, Tx at 26 mo
17. 56/F 6 13.1 2HRZ+4HR 16.55
18. 54/F 12 15.5 2HRZ+4HR 21.9
19. 40/F 18 12.1 2HRZE+4HR 9.8
20. 71/M 50 16.5 2HRZ+4HR 12.5
21. 39/M 36 66 2HRZ+4HR 40
22. 29/F 26 27.8 2HRZ+4HR 90.8
23. 26/F 13 12.42 2HRZ+4HR 21.67
24. 61/F 12 5.9 2HRZ4HR 49.11
25. 38/F 22 5.37 2HRZ+4HR HDx immediately
Abbreviations: E, ethambutol; eGFR, estimated glomerular filtration rate in ml/min; F/U, follow-up; H, isoniazid; HDx, hemodialysis; mo, month; PD, peritoneal dialysis;
R, rifampicin; Tx, transplantation; Z, pyrazinamide.
aNumbers denote treatment duration in months.
bH-resistant organism isolated from sputum, given moxifloxacin (Mox) 400 mg OD.
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were Somalian whereas one was of Ethiopian origin. The
patients with HIV co-infection were from Uganda and Zambia.
Autoimmune renal vasculitis has been reported in a large
autopsy series of patients with Mycobacterium leprae infec-
tion, with 14% patients having glomerulonephritis and 9%
having TIN.23 It has been suggested that immune activation
leading to an immune complex nephritis can be a cause of
renal failure in mycobacterial infections.11 Our group
of patients presented with TIN with or without granulomata
formation; the incidence of caseating necrosis or stain-
positive M. tuberculosis was low. EMU samples for
M. tuberculosis were negative in all patients, apart from one
patient with HIV infection, lending credence to the
hypothesis that this TIN is secondary to a pauci-bacillary
immune reaction. However, there was no evidence of
immune-complex deposition on electron microscopy and
no specific pattern of complement or immunoglobulin
deposition noted in these patients. EMU samples, and the
presence or absence of sterile leukocyturia, are not helpful in
the diagnosis of TB TIN. There was good response
to combined antitubercular and steroid treatment in terms
of systemic symptoms, disease elsewhere, and stabilization of
renal function in the subgroup of patients who presented
with an eGFR of 415ml/min and with less interstitial
fibrosis and glomerular atrophy.
There is some evidence of over-representation of idio-
pathic TIN in the Indian population in the United Kingdom
compared with other ethnic groups in a previous series from
London.12 It is not clear in that report whether the patients
treated with oral steroids (with isoniazid prophylaxis) were
those with granulomatous TIN; none of these patients were
reported to have been treated for TB or reactivated TB during
follow-up. Two patients in our series who were treated
with systemic corticosteroids became systemically unwell
(despite isoniazid prophylaxis), developed disseminated TB,
and went on to receive antitubercular treatment, suggesting
that treatment with steroids alone is not without risks.
Out of the 17 patients who presented with an MDRD
eGFR19 of o15ml/min, 11 patients had a poor renal
outcome and progressed to renal replacement therapy within
12 months of presentation. Those patients who presented
with an MDRD eGFR of415ml/min showed stabilization of
their renal function up to 2 years after the initiation of
treatment with antitubercular treatment. However, their renal
function started deteriorating after 2 years post-treatment.
We feel this could have been because of tubular and
glomerular atrophy associated with the previous disease.
It is noteworthy that only 10 out of the 25 (40%) were known
to medical services in the United Kingdom for 46 months
before diagnosis, and 9 (36%) presented with end-stage
chemistry or near end-stage chemistry, requiring dialysis
within 6 months of presentation.
This series demonstrates that TB TIN often presents late
with advanced disease. A low threshold of suspicion in high-
risk populations might lead to earlier diagnosis; early
diagnosis and treatment can preserve renal function and
delay initiation of renal replacement therapy. Treatment is
important in this group as it can influence patient morbidity
and mortality because of TB as well as renal replacement
therapy. The optimal duration of antitubercular treatment
and the role of corticosteroid treatment in this condition
require further investigation.
MATERIALS AND METHODS
Identification of cases and definitions
We identified 25 patients referred to the Barts and the Royal London
Hospital Renal unit during the period January 2001 to August 2007
with TB and renal disease. The indications for renal biopsy were
unexplained progressive renal impairment and proteinuric renal
disease with or without a previous history of TB. Contraindications
were small kidneys on renal imaging or a single-functioning kidney.
In 17 patients, a native renal biopsy was indicated and technically
possible; all showed TIN. The breakdown of the whole cohort is in
Figure 1. The patients with TIN were analyzed with respect to
epidemiological and clinical features, including response to therapy
with anti-TB treatment and corticosteroids, and length of follow-up.
The eGFR was calculated by the four-variable MDRD equation.
Histological analysis
Renal biopsy samples were processed in the routine manner and
embedded in paraffin wax. The sections were stained with
hematoxylin and eosin and Ziehl–Neelsen staining. All of the
specimens were reported by two observers and discussed in a
clinicopathological conference, with the changes within glomeruli,
tubules, interstitium, and vessels documented. These included
tubulitis, interstitial inflammation, scarring, and the presence or
absence of granulomas, and/or acid and alcohol fast bacilli.
Granulomatous TIN was defined as interstitial nephritis in which
the inflammatory infiltrate included one or more aggregates of
epithelioid cells, with or without ceseation and with or without
multinucleate giant cells.
Statistics
GraphPad Prism version 5.00 for Windows XP (GraphPad Software,
San Diego, CA) was used for the analysis. Paired t-test was used
to compare year 0, month 6, year 1, and last documented eGFR in
different groups, whereas Student’s t-test was used to compare
change in proteinuria before and after treatment. A P-value of
o0.05 was considered significant. Spearman’s rank coefficient was
used to correlate renal function with proteinuria.
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